Language Selector:

Lungpacer Medical Announces Premarket Approval for AeroPace® System

Exton, PA – December 5, 2024 – Lungpacer Medical, a neurostimulation company dedicated to developing innovative interventional therapies to free patients from mechanical ventilation (MV) and improve diaphragm, lung, heart, and brain health, today announced premarket approval (PMA) from the U.S. Food and Drug Administration

Read More

Lungpacer Media

For media inquiries, please email info@lungpacer.com.